DG051 structure
|
Common Name | DG051 | ||
---|---|---|---|---|
CAS Number | 929915-58-2 | Molecular Weight | 426.33400 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C21H25Cl2NO4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of DG051DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC50=47 nM. |
Name | 4-{(S)-2-(4-(4-chlorophenoxy)phenoxymethyl)pyrrolidin-1-yl}-1-butyric acid hydrochloride |
---|---|
Synonym | More Synonyms |
Description | DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC50=47 nM. |
---|---|
Related Catalog | |
Target |
IC50: 47 nM (LTA4H)[1] |
In Vitro | DG051 is a potent inhibitor of LTA4H aminopeptidase activity against L-alanine p-nitroanilide (IC50=72 nM). DG051 inhibits human whole blood (HWB) with IC50 of 37 nM. As applied within the context of LTA4H inhibitor design, the chemistry team is able to design a potent DG051(Kd=26 nM) with high aqueous solubility (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clinical evaluation for the treatment of myocardial infarction and stroke[1] DG-051 is a first-in-class small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), currently in Phase II clinical development for the prevention of heart attack[2]. |
References |
Molecular Formula | C21H25Cl2NO4 |
---|---|
Molecular Weight | 426.33400 |
Exact Mass | 425.11600 |
PSA | 59.00000 |
LogP | 5.58020 |
Storage condition | 2-8℃ |
Precursor 1 | |
---|---|
DownStream 1 | |
4-{(S)-2-[4-(4-Chloro-phenoxy)-phenoxymethyl]-pyrrolidin-1-yl}-butyric acid hydrochloride |
4-{(2S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}butyric acid hydrochloride |
4-{(S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}butyric acid hydrochloride |
DG-051 HYDROCHLORIDE |
DG051 |